Phenylethyl-substituted pyrimido[2,1-f]purinediones and related compounds: Structure-activity relationships as adenosine A1 and A2A receptor ligands

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 22, 2007, Pages 6956-6974

  Drabczyńska, Anna ^a   Müller, Christa E ^b   Schiedel, Anke ^b   Schumacher, Britta ^b   Karolak Wojciechowska, Janina ^c   Fruziński, Andrzej ^c   Zobnina, Weronika ^a   Yuzlenko, Olga ^a   Kieć Kononowicz, Katarzyna ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF BONN   (Germany)

^c LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

A2A receptor ligands; Adenosine A1; Anticonvulsant activity; Pyrimido 2,1 f purinediones; Tricyclic xanthine derivatives

Indexed keywords

1,3 DIMETHYL 9 (4 CHLOROPHENOXYETHYL) 6,7,8,9 TETRAHYDROPYRIMIDO[2,1 F]PURINE 2,4(1H,3H) DIONE; 1,3 DIMETHYL 9 [2 (4 METHYLPHENOXY)ETHYL] 6,7,8,9 TETRAHYDROPYRIMIDO[2,1 F]PURINE 2,4(1H,3H) DIONE; 1,3 DIMETHYL 9 [2 (BENZYLAMINO)ETHYL] 6,7,8,9 TETRAHYDROPYRIMIDO[2,1 F]PURINE 2,4(1H,3H) DIONE; 1,3 DIMETHYL 9 [2 (BENZYLOXY)ETHYL] 6,7,8,9 TETRAHYDROPYRIMIDO[2,1 F]PURINE 2,4(1H,3H) DIONE; 7 (3 CHLOROPROPYL) 8 BROMO 1,3 DIPROPYLXANTHINE; 7 (3 CHLOROPROPYL) 8 BROMOTHEOPHYLLINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; AROMATIC COMPOUND; CARBAMIC ACID; ETHYLENE; LIGAND; NITROGEN; OXYGEN; PURINE DERIVATIVE; RECEPTOR SUBTYPE; THEOPHYLLINE DERIVATIVE; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOM; CHEMICAL BOND; CONTROLLED STUDY; CONVULSION; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; ELECTRICITY; IN VIVO STUDY; LIPOPHILICITY; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PHYSICAL CHEMISTRY; RECEPTOR AFFINITY; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY;

ANIMALS; ANTICONVULSANTS; BINDING SITES; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAPERITONEAL; LIGANDS; MALE; MICE; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PURINES; RECEPTOR, ADENOSINE A1; RECEPTORS, ADENOSINE A2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 34548830693     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.07.051     Document Type: Article

References (54)

1. Fredholm B.B., IJzerman A.P., Jacobson K.A., Klotz K.-N., and Linden J. Pharmacol. Rev. 53 (2001) 527
2. Ralevic V., and Burnstock G. Pharmacol. Rev. (1998) 50
3. Müller C.E. Curr. Med. Chem. 7 (2000) 1269
4. Dhalla A.K., Shryock J.C., Shreeniwas R., and Bellardinelli L. Curr. Top. Med. Chem. 3 (2003) 369
5. Poulsen S.-A., and Quinn R.J. Bioorg. Med. Chem. 6 (1998) 619
6. Müller C.E. Exp. Opin. Ther. Patents 7 (1997) 419
7. Hess S. Exp. Opin. Ther. Patents 11 (2001) 1533
8. Yuzlenko O., and Kieć-Kononowicz K. Curr. Med. Chem. 13 (2006) 3609
9. Müller C.E. Drugs Future 25 (2000) 1043
10. Baraldi P.G., Tabrizi M.A., Bovero A., Avitabile B., Preti D., Fruttarolo F., Romagnoli R., Varani K., and Borea P.A. Eur. J. Med. Chem. 38 (2003) 367
11. Rockitt S., Duddeck H., Drabczyńska A., and Kieć-Kononowicz K. Eur. J. Org. Chem. (2000) 3489
12. Kieć-Kononowicz K., Drabczyńska A., Pe{ogonek}kala E., Michalak B., Müller C.E., Schumacher B., Karolak-Wojciechowska J., Duddeck H., Rockitt S., and Wartchow R. Pure Appl. Chem. 73 (2001) 1411
13. Drabczyńska A., Schumacher B., Müller C.E., Karolak-Wojciechowska J., Michalak B., Pe{ogonek}kala E., and Kieć-Kononowicz K. Eur. J. Med. Chem. 38 (2003) 397
14. Drabczyńska A., Müller C.E., Schumacher B., Hinz S., Karolak-Wojciechowska J., Michalak B., Pe{ogonek}kala E., and Kieć-Kononowicz K. Bioorg. Med. Chem. 12 (2004) 4895
15. Drabczyńska A., Müller C.E., Lacher S.K., Schumacher B., Karolak-Wojciechowska J., Nasal A., Kawczak P., Yuzlenko O., Pe{ogonek}kala E., and Kieć-Kononowicz K. Bioorg. Med. Chem. 14 (2006) 7258
16. Drabczyńska A., Müller C.E., Karolak-Wojciechowska J., Schumacher B., Schiedel A., Yuzlenko O., and Kieć-Kononowicz K. Bioorg. Med. Chem. 15 (2007) 5003
17. Rockitt S., Wartchow R., Duddeck H., Drabczyńska A., and Kieć-Kononowicz K. Z. Naturforsch. 56b (2001) 319
18. Pawłowski M., Drabczyńska A., Gorczyca M., Malec D., and Modzelewski J. Pol. J. Pharm. 43 (1991) 61
19. Eckstein M. Dissert. Pharm. 14 (1962) 435
20. Mitsunobu O. Synthesis (1981) 1
21. El-Shaieb K.M. Heteroat. Chem. 17 (2006) 365
22. McCarroll A.J., Sandham D.A., Titcomb L.R., de K. Lewis A.K., Cloke F.G.N., Davies B.P., Perez de Santana A., Hiller W., and Caddick S. Mol. Divers. 7 (2003) 115
23. Bergmann F., and Dikstein S. J. Am. Chem. Soc. 77 (1955) 691
24. Rybár A., and Antoš K. Collect. Czech. Chem. Commun. 35 (1970) 1415
25. Müller C.E., Maurinsh J., and Sauer R. Eur. J. Pharm. Sci. 10 (2000) 259
26. Klotz K.-N., Lohse M.J., Schwabe U., Cristalli G., Vittori S., and Grifantini M. Naunyn Schmiedeberg's Arch. Pharmacol. 340 (1989) 679
27. Ji X.-D., and Jacobson K.A. Drug Des. Discov. 16 (1999) 217
28. Yan L., and Müller C.E. J. Med. Chem. 47 (2004) 1031
29. Yan L., Bertarelli D.C.G., Hayallah A.M., Meyer H., Klotz K.-N., and Müller C.E. J. Med. Chem. 49 (2006) 4384
30. Müller C.E., Diekmann M., Thorand M., and Ozola V. Bioorg. Med. Chem. Lett. 12 (2002) 501
31. Porter R.J., Cereghino J.J., Gladding G.D., Kupferberg H.J., Scoville B., and White B.G. Clev. Clin. 51 (1984) 293
32. Krall R.L., Penry J.K., White B.G., Kupferberg H.J., and Swinyard E.A. Epilepsia 19 (1978) 409
33. Stables J.P., and Kupferberg K.J. Molecular and Cellular Targets for Antiepileptic Drugs (1998), John Libbey, London 191-198
34. Barton M.E., Klein B.D., Wolf H.H., and White S. Epilepsy Res. 47 (2001) 217
35. Kaminski R.M., Livingood M.R., and Rogawski M.R. Epilepsia 45 (2004) 864
36. Gao Z.G., and IJzerman A.P. Biochem. Pharmacol. 60 (2000) 669
37. CAChe, Version 6.1.1. Sunnyvale, Fujitsu Computer Systems, 2002.
38. Hawkins D.M., Basak S.C., and Mills D. J. Chem. Inf. Comput. Sci. 43 (2003) 579
39. Golbraikh A., Shen M., Xiao Z., De Xiao Y., Lee K.-H., and Tropsha A. J. Comp. Aided Mol. Des. 17 (2003) 241
40. Golbraikh A., and Tropsha A. J. Mol. Graphics Modell. 20 (2002) 269
41. Hawkins D.M. J. Chem. Inf. Comput. Sci. 44 (2004) 1
42. Cronin M.T., and Schultz T.W. THEOCHEM 622 (2003) 39
43. He L., and Jurs P.C. J. Mol. Graphics Modell. 23 (2005) 503
44. Verma R.P., and Hansch C. Bioorg. Med. Chem. 13 (2005) 4597
45. Hockemeyer J., Burbiel J.C., and Müller C.E. J. Org. Chem. 69 (2004) 3308
46. Burbiel J., Thorand M., and Müller C.E. Heterocycles 60 (2003) 1425
47. Bertarelli, D. C. G.; Diekmann, M.; Hayallah, A. M.; Rüsing, D.; Iqbal, J.; Preiss, B.; Verspohl, E. J.; Müller, C. E. Purinergic Signalling, in press.
48. Bulicz J., Bertarelli D.C.G., Baumert D., Fülle F., Müller C.E., and Heber D. Bioorg. Med. Chem. 14 (2006) 2837
49. Klotz K.-N., Hessling J., Hegler J., Owman C., Kull B., Fredholm B.B., and Lohse M.J. Naunyn Schmiedeberg's Arch. Pharmacol. 357 (1998) 1
50. Hayallah A.M., Sandoval-Rami{dotless}́rez J., Reith U., Schobert U., Preiss B., Schumacher B., Daly J.W., and Müller C.E. J. Med. Chem. 45 (2002) 1500
51. Sauer R., Maurinsh J., Reith U., Fülle F., Klotz K.-N., and Müller C.E. J. Med. Chem. 43 (2000) 440
52. MT, Siemens Analytical X-Ray Instruments Inc., Madison, Wisconsin, USA, 1990.
53. Sheldrick G. M. SHELXL-97.A FORTRAN-77 Program for the Refinement of Crystal Structures from Diffraction Data. University of Göttingen, Germany, 1997.
54. PCMODEL 6 Molecular Modeling Software for the IBM PC, Serena Software, Bloomington; 1996.